Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Tafuri

Showing results (61-70 of 88) with videos related to

Pageof 9
Sort By:
Diabetes|July 1, 1990
Intrinsic cytotoxicity of natural killer cells to pancreatic islets in vitroN Nakamura, B A Woda, A Tafuri, et al.
The New England Journal of Medicine|May 26, 1991
Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid)R P Warrell, S R Frankel, W H Miller, et al.
Bone Marrow Transplantation|August 26, 1998
Flt3L enhances the early stem cell compartment after ex vivo amplification of umbilical cord blood CD34+ cellsL De Felice, T Di Pucchio, M Breccia, et al.
Leukemia|April 24, 1999
Outpatient management of acute promyelocytic leukemia after consolidation chemotherapyC Girmenia, R Latagliata, S Tosti, et al.
Haematologica|September 8, 1999
Out-patient management of acute myeloid leukemia after consolidation chemotherapy. Role of a hematologic emergency unitC Girmenia, G Alimena, R Latagliata, et al.
British Journal of Haematology|August 6, 2000
t(4;11)(q21;p15) translocation involving NUP98 and RAP1GDS1 genes: characterization of a new subset of T acute lymphoblastic leukaemiaC Mecucci, R La Starza, M Negrini, et al.
Scientific Reports|May 16, 2023
Regional long-term analysis of dietary isotopes in Neolithic southeastern Italy: new patterns and research directionsM A Tafuri, S Soncin, S Panella, et al.
Annals of Hematology|July 2, 2003
High-dose hydroxyurea in the treatment of poor-risk myeloid leukemiasM C Petti, A Tafuri, R Latagliata, et al.
La Clinica Terapeutica|May 26, 2010
[Budd-Chiari syndrome and splanchnic vein thrombosis: masked myeloproliferative neoplasms and JAK2V617F]A Fama, A Rago, F Gioiosa, et al.
Leukemia|September 19, 2008
Targeting the leukemic stem cell: the Holy Grail of leukemia therapyN Misaghian, G Ligresti, L S Steelman, et al.
Pageof 9

Showing results (61-70 of 88) with videos related to

Sort By:
Pageof 9
Diabetes|July 1, 1990
Intrinsic cytotoxicity of natural killer cells to pancreatic islets in vitroN Nakamura, B A Woda, A Tafuri, et al.
The New England Journal of Medicine|May 26, 1991
Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid)R P Warrell, S R Frankel, W H Miller, et al.
Bone Marrow Transplantation|August 26, 1998
Flt3L enhances the early stem cell compartment after ex vivo amplification of umbilical cord blood CD34+ cellsL De Felice, T Di Pucchio, M Breccia, et al.
Leukemia|April 24, 1999
Outpatient management of acute promyelocytic leukemia after consolidation chemotherapyC Girmenia, R Latagliata, S Tosti, et al.
Haematologica|September 8, 1999
Out-patient management of acute myeloid leukemia after consolidation chemotherapy. Role of a hematologic emergency unitC Girmenia, G Alimena, R Latagliata, et al.
British Journal of Haematology|August 6, 2000
t(4;11)(q21;p15) translocation involving NUP98 and RAP1GDS1 genes: characterization of a new subset of T acute lymphoblastic leukaemiaC Mecucci, R La Starza, M Negrini, et al.
Scientific Reports|May 16, 2023
Regional long-term analysis of dietary isotopes in Neolithic southeastern Italy: new patterns and research directionsM A Tafuri, S Soncin, S Panella, et al.
Annals of Hematology|July 2, 2003
High-dose hydroxyurea in the treatment of poor-risk myeloid leukemiasM C Petti, A Tafuri, R Latagliata, et al.
La Clinica Terapeutica|May 26, 2010
[Budd-Chiari syndrome and splanchnic vein thrombosis: masked myeloproliferative neoplasms and JAK2V617F]A Fama, A Rago, F Gioiosa, et al.
Leukemia|September 19, 2008
Targeting the leukemic stem cell: the Holy Grail of leukemia therapyN Misaghian, G Ligresti, L S Steelman, et al.
Pageof 9